Immunophotonics Completes Treatment of Last Patient in INJECTABL-1 Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors

Immunophotonics has reached a major milestone in its clinical development efforts with the completion of treatment for the final patient in the INJECTABL-1 Phase 1b/2a trial of IP-001 for advanced solid tumors. The 41-patient, multicenter trial was conducted across the U.S., UK, France, Germany, and Switzerland, targeting colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma. IP-001, our proprietary glycan polymer, is designed to transform routine tumor ablation into a personalized systemic cancer immunotherapy. We thank our partners, investigators, and especially all patients who made this milestone possible. Official Press Release Print

The release as fetched from its publisher. immunophotonics.com ↗